Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma
Brief Summary: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma.

PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: BEACOPP escalated | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPP escalated | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: BEACOPP escalated | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): B | Intervention Type: DRUG; Name: BEACOPP escalated; Assigned to Arm(s): A, B, C, D
B: Arm Label: Group 1 (favorable prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 2 (intermediate prognosis); Type: EXPERIMENTAL; Interventions: Biological: bleomycin sulfate, Drug: ABVD regimen, Drug: carmustine, Drug: dacarbazine, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: methylprednisolone, Drug: vincristine sulfate, Drug: vindesine | Arm Label: Group 3 (poor prognosis); Type: EXPERIMENTAL; Interventions: Drug: carmustine, Drug: cisplatin, Drug: cytarabine, Drug: dexamethasone, Drug: doxorubicin hydrochloride, Drug: etoposide, Drug: gemcitabine hydrochloride, Drug: ifosfamide, Drug: melphalan, Drug: methylprednisolone, Drug: mitoguazone, Drug: vindesine, Drug: vinorelbine tartrate, Procedure: allogeneic hematopoietic stem cell transplantation, Procedure: autologous hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: bleomycin sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: ABVD regimen; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: carmustine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: dacarbazine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: ifosfamide; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: melphalan; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: mitoguazone; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vincristine sulfate; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis) | Intervention Type: DRUG; Name: vindesine; Assigned to Arm(s): Group 1 (favorable prognosis), Group 2 (intermediate prognosis), Group 3 (poor prognosis) | Intervention Type: DRUG; Name: vinorelbine tartrate; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: allogeneic hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis) | Intervention Type: PROCEDURE; Name: autologous hematopoietic stem cell transplantation; Assigned to Arm(s): Group 3 (poor prognosis)
C: Arm Label: Treatment (chemotherapy and F-18 PET/CT); Type: EXPERIMENTAL; Interventions: Biological: Bleomycin Sulfate, Drug: Doxorubicin Hydrochloride, Drug: Procarbazine Hydrochloride, Drug: Vinblastine Sulfate, Drug: Dacarbazine, Drug: Cyclophosphamide, Drug: Etoposide phosphate, Drug: prednisone, Drug: Radiation Therapy, Radiation: Fludeoxyglucose F-18, Procedure: computed tomography, Procedure: Positron Emission Tomography | Intervention Type: BIOLOGICAL; Name: Bleomycin Sulfate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Doxorubicin Hydrochloride; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Procarbazine Hydrochloride; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Vinblastine Sulfate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Etoposide phosphate; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: DRUG; Name: Radiation Therapy; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: RADIATION; Name: Fludeoxyglucose F-18; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: PROCEDURE; Name: computed tomography; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT) | Intervention Type: PROCEDURE; Name: Positron Emission Tomography; Assigned to Arm(s): Treatment (chemotherapy and F-18 PET/CT)
D: Arm Label: Standard arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: BEACOPPesc | Arm Label: Experimental arm; Type: EXPERIMENTAL; Interventions: Drug: BEACOPPesc - ABVD - PET2 | Intervention Type: DRUG; Name: BEACOPPesc; Assigned to Arm(s): Standard arm | Intervention Type: DRUG; Name: BEACOPPesc - ABVD - PET2; Assigned to Arm(s): Experimental arm

Answer: B